Fortrea (FTRE) vs Veracyte (VCYT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Fortrea (FTRE) has outperformed Veracyte (VCYT) over the past year, gaining 120.8% versus a gain of 24.7%. Veracyte is the larger company by market cap ($3.47 billion vs $1.90 billion), about 1.8 times the size. On valuation, Fortrea trades at a lower forward P/E (17.5x vs 22.2x for Veracyte).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FTRE | VCYT |
|---|---|---|
| Share price | $19.98 | $43.20 |
| Market cap | $1.90B | $3.47B |
| 1-day change | -2.82% | +0.09% |
| YTD return | +19.19% | +2.52% |
| 1-year return | +120.84% | +24.70% |
| 5-year return | — | -4.43% |
| P/E ratio (TTM) | — | 30.86 |
| Forward P/E | 17.45 | 22.15 |
| EPS (TTM) | $-0.91 | $1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $517.14M |
| Revenue growth (YoY) | — | +16.01% |
| Net income (latest FY) | — | $66.35M |
| Gross margin | — | 70.10% |
| Operating margin | — | 11.17% |
| Net margin | — | 12.83% |
| 52-week high | $23.51 | $60.91 |
| 52-week low | $8.55 | $29.46 |
| Distance from 52-week high | -15.01% | -29.08% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +4.25% | +35.23% |
| Average volume | 1.47M | 1.35M |
| Shares outstanding | 95.10M | 80.39M |
| Employees | 14,000 | 755 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTRE has outperformed VCYT by 96.1 percentage points over the past year.
About Fortrea
FTRE stock →Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services.
Health Care · Medical Specialities · 14,000 employees
About Veracyte
VCYT stock →Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Health Care · Medical Specialities · 755 employees
FTRE vs VCYT FAQ
Which is bigger, Fortrea or Veracyte?
Veracyte (VCYT) is larger, with a market capitalization of $3.47B compared with $1.90B for Fortrea (FTRE).
Which stock has performed better over the past year, FTRE or VCYT?
FTRE returned +120.84% over the past 12 months, compared with +24.70% for VCYT (price return, excluding dividends). Past performance does not predict future results.
Are Fortrea and Veracyte in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.